




A**B****C**

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12






Figure 13

14/19




(a)




(b)

Figure 14




(a)




(b)

Figure 15

16/19




(a)




(b)

Figure 16



(a)



(b)

Figure 17

18/19

Drug	Parental MDA231 (IC ₅₀ , M)	Paclitaxel- treated MDA231 (IC ₅₀ , M)	Fold change (paclitaxel- treated vs parental)
Paclitaxel	4.62e-09	2.65e-07	57.38
Doxorubicin	1.97e-07	0.000001	6.55
Vincristine	9.32e-10	4.38e-09	4.70
5-FU	0.00004	0.00007	1.64
Cisplatin	5.40e-05	5.76e-05	1.07
Gemcitabine	3.30e-07	2.93e-07	0.89
Pacritinib	0.000003	8.85e-07	0.31

Figure 17 (c)

19/19




Figure 18